Patents by Inventor Haishan Li

Haishan Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12370253
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: July 29, 2025
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeffrey A. Galvin
  • Patent number: 12359203
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: July 15, 2025
    Assignee: AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • Publication number: 20250121050
    Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: August 19, 2024
    Publication date: April 17, 2025
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen
  • Publication number: 20250121051
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: October 22, 2024
    Publication date: April 17, 2025
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeffrey Galvin
  • Patent number: 12090200
    Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include methods for making cells resistant to HIV and administering an immune therapy to an HIV-negative subject to prevent an HIV infection.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 17, 2024
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen
  • Publication number: 20240279678
    Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.
    Type: Application
    Filed: March 3, 2021
    Publication date: August 22, 2024
    Inventors: Haishan Li, Tyler Lahusen, Charles David Pauza
  • Publication number: 20240238406
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: December 14, 2023
    Publication date: July 18, 2024
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
  • Publication number: 20240141374
    Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Inventors: Haishan Li, Tyler Lahusen, Charles David Pauza
  • Publication number: 20240115604
    Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include purifying peripheral blood mononuclear cells (PBMC) from a source, stimulating the PBMC with at least one HIV-specific peptide, depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, CD4+ T cells, ?? cells, NK cells, B cells, T regulatory cells, and NKT cells, transducing the depleted PBMC with a viral delivery system encoding at least one genetic element, culturing the transduced PBMC for at least one day, and harvesting the cultured PBMC.
    Type: Application
    Filed: July 28, 2023
    Publication date: April 11, 2024
    Inventors: Haishan Li, Charles David Pauza
  • Publication number: 20240108714
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: July 28, 2023
    Publication date: April 4, 2024
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeffrey A. Galvin
  • Publication number: 20240091339
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 21, 2024
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
  • Publication number: 20240075140
    Abstract: The present disclosure relates generally to modified NK cell compositions and methods of using the modified cell compositions in immunotherapy applications. In embodiments, the modified cell express a ? chain and a ? chain. In embodiments, the modified NK cell compositions can be used to treat various cancers.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 7, 2024
    Inventors: Haishan Li, Tyler Lahusen, Charles David Pauza
  • Patent number: 11911458
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 27, 2024
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
  • Publication number: 20230340531
    Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
    Type: Application
    Filed: November 1, 2022
    Publication date: October 26, 2023
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
  • Publication number: 20230277579
    Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 7, 2023
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
  • Publication number: 20230241200
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeffrey Galvin
  • Patent number: 11612649
    Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: March 28, 2023
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeff Galvin
  • Patent number: 11534450
    Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 27, 2022
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
  • Patent number: 11519006
    Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 6, 2022
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
  • Patent number: D1039357
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: August 20, 2024
    Inventor: Haishan Li